Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Kiniksa Pharmaceuticals, Ltd. Banner

Kiniksa Pharmaceuticals, Ltd.

KNSA Stock Analysis

Page title

Section title

Breakdown
2016
2017
2018
2019
2020
2021
2022
2023
Net Income
-23.973m-64.873m-103.227m-161.867m-161.381m-157.924m183.363M14.084M
Depreciation & Amortization
22.000K28.000K286.000K2.068M2.405M2.355M2.402M2.109M
Change in Working Capital
1.762M13.926M18.328M-17.025m-4.315m689.000K-22.575m1.350M
Operating Cash Flow
-21.867m-50.219m-81.012m-158.369m-136.532m-126.298m5.807M13.301M
Capital Expenditure
-3.000k-69.000k-5.290m-3.203m-283.000k-20.415m-105.000k-130.000k
Free Cash Flow
-21.870m-50.288m-86.302m-161.572m-136.815m-146.713m5.702M13.171M
Debt Repayment
0.0000.0000.0000.0000.0000.0000.0000.000
Dividends Paid
0.0000.0000.0000.0000.0000.0000.0000.000
Common Stock Issued
42.509M39.873M159.194M84.107M227.086M5.885M3.417M1.495M
Common Stock Repurchased
0.0000.0000.0000.0006.553M5.885M-901.000k-2.206m
Net Change in Cash
20.639M-10.415m26.526M-25.048m67.110M8.222M245.000K-14.761m